METHOD FOR PREDICTION OF CLINICAL EFFECTIVENESS OF INTERFERON THERAPY OF CHRONIC HEPATITIS C IN CHILDREN Russian patent published in 2013 - IPC G01N33/533 

FIELD: medicine.

SUBSTANCE: determining an initial level of total lymphocyte count ≥2500/mcl and CD16+56+ lymphocyte ≥440/mcl count is considered a positive prognostic factor of a virologic reponse to the interferon therapy. An initial level of total lymphocyte count ≤2000/mcl and CD 16+56+ lymphocyte count ≤440/mcl is considered a negative prognostic factor of a virologic reponse. The initial level of total lymphocyte count within the range of 2000-2500 is considered an indication of a follow-up care with underlying treatment. Then, 12 weeks after the interferon therapy, total lymphocyte count, CD3+ lymphocyte count, CD3+CD4+ lymphocyte count and CD16+56+ lymphocyte count in 1 mcl are determined. If observing an increase in total lymphocyte count ≥2500/mcl, CD3+ lymphocyte count ≥1900/mcl, CD3+CD4+lymphocyte count ≥1000/mcl and CD16+56+ lymphocyte count >440/mcl in relation to the initial level, a positive prognosis of the clinical effectiveness of the interferon therapy is concluded.

EFFECT: using the given method enables predicting the clinical effectiveness of the interferon therapy before the beginning thereof and ensuring an individual approach to prescribing the therapy in chronic hepatitis C.

2 ex